1. ALLA AKTIER
  2. NYHETER
  3. CINCLUS PHARMA

Cinclus Pharma

Nyheter Cinclus Pharma Nyheter alla bolag

Cinclus Pharma publishes its Annual Report for 2024

REG

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing molecules for the treatment of gastric acid-related diseases, today announced that its Annual Report for 2024 has been published.

The Annual Report is available at https://cincluspharma.com/investors/financial-reports/. The Swedish version of the report is also available in European Single Electronic Format (ESEF).

“The trend is clear. In many of the countries and regions where first-generation PCABs are launched, these are gradually taking over the market from the old proton pump inhibitors (PPIs). Our ambition is to develop a unique next-generation PCAB that meets the medical need and provides the conditions to do exactly what AstraZeneca did when they launched the next-generation PPI, Nexium, twelve years after the introduction of Losec, i.e. to take over the market”, says Christer Ahlberg, CEO, Cinclus Pharma.
 

For additional information, please contact:

Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com

Henrik Vikström, IR
Phone: +46 70 952 80 06
e-mail: henrik.vikström@cincluspharma.com

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.

This information is information that Cinclus Pharma Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-17 14:00 CEST.

Attachments

Cinclus Pharma Annual Report 2024

Datum 2025-04-17, kl 14:00
Källa MFN
Bifogade filer
Cinclus Pharma Annual Report 2024
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet